Arcturus Therapeutics Holdings Inc (NQ:ARCT)

Arcturus Therapeutics (NASDAQ:ARCT) presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to...

Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform ↗

September 24, 2026

Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform

Performance

52-Week Range 37.5% below 52-week high

11.23

5.5052W Low 17.9652W High

1 Week 2.5% below 1-week high

9.651W Low 11.521W High

Arcturus Therapeutics Holdings Inc (ARCT) traded between $5.50 and $17.96 over the past 52 weeks and last traded at $11.23, 37.5% below its 52-week high. Over the past week it ranged between $9.65 and $11.52.

Past 12 Months

+2.3%

-22.3%

+95.0%

+35.3%

+79.7%

+6.0%

1W +$0.25

1M -$3.23

3M +$5.47

6M +$2.93

YTD +$4.98

1Y +$0.64

ARCT was +6.0% over the past year, +35.3% over six months, +79.7% year to date, +2.3% in the last week.

12 Months vs Market

ARCT

+6.0%

DIA

+10.1%

SPY

+12.3%

QQQ

+14.8%

IWM

+11.9%

Over the past 12 months ARCT returned +6.0% versus DIA (Dow) +10.1%, SPY (S&P 500) +12.3%, QQQ (Nasdaq 100) +14.8% and IWM (Russell 2000) +11.9%.

Volume & Liquidity 0.98× 3-mo avg

Today 924,222 3-mo avg 942.2K

550.7K

635.9K

942.2K

712.7K

YTD

623.9K

679.1K

ARCT most recently traded 924,222 shares against a 3-month average daily volume of 942.2K.

More News

September 23, 2026

Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform

September 18, 2026

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q1 2026 Results: Revenue Miss Weighs on Sentiment as Pipeline Advances ↗

May 07, 2026

Via Chartmill

Arcturus Therapeutics to Participate in Upcoming Investor Conferences

August 31, 2026

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

August 19, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's pre-market session. ↗

August 19, 2026

Via Chartmill

Arcturus (ARCT) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Via The Motley Fool

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline ↗

August 11, 2026

Arcturus Therapeutics Q2 Earnings Call Highlights ↗

August 06, 2026

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

August 06, 2026

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026

July 28, 2026

Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

July 20, 2026

Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis

Thursday's session: gap up and gap down stocks ↗

July 02, 2026

Via Chartmill

July 02, 2026

Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies ↗

June 05, 2026

Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

May 26, 2026

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

Arcturus (ARCT) Q1 2026 Earnings Call Transcript ↗

May 08, 2026

Via The Motley Fool

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

May 07, 2026

Via Chartmill

May 07, 2026

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026

April 27, 2026